Genscript Biotech Co. (OTCMKTS:GNNSF – Get Free Report)’s share price fell 15.5% during trading on Monday . The company traded as low as C$1.31 and last traded at C$1.31. 200 shares were traded during mid-day trading, a decline of 98% from the average session volume of 9,917 shares. The stock had previously closed at C$1.55.
Genscript Biotech Price Performance
The company has a 50-day moving average price of C$1.75 and a two-hundred day moving average price of C$2.03.
Genscript Biotech Company Profile
GenScript Biotech Corporation is a global contract research, development and manufacturing organization (CDMO) specializing in synthetic biology and biopharmaceutical services. Founded in 2002, the company provides end-to-end solutions that span gene and peptide synthesis, recombinant protein expression, custom antibody discovery and cell line development. GenScript’s integrated platforms support early-stage discovery through to process development, enabling academic institutions, biotech innovators and pharmaceutical companies to accelerate research timelines.
The company’s core offerings include molecular biology services such as DNA construction, gene editing using CRISPR/Cas9 technology and high-throughput peptide libraries.
See Also
- Five stocks we like better than Genscript Biotech
- Buy this Gold Stock Before May 15th, 2026
- America’s 1776 happening again
- J.P. Morgan is betting on this coin
- Central banks just did something they haven’t done since 1967
- My Epstein Story
Receive News & Ratings for Genscript Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genscript Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
